The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) neurons, which, respectively, define the peripheral and central GLP-1 systems. PPG neurons in the nucleus tractus solitarii (NTS) are widely assumed to link the peripheral and central GLP-1 systems in a unified gut–brain satiation circuit. However, direct evidence for this hypothesis is lacking, and the necessary circuitry remains to be demonstrated. Here we show that PPGNTS neurons encode satiation in mice, consistent with vagal signalling of gastrointestinal distension. However, PPGNTS neurons predominantly receive vagal input from oxytocin-receptor-expressing vagal neurons, rather than those expressing GLP-1 receptors. PPGNTS neurons are not necessary for eating suppression by GLP-1 receptor agonists, and concurrent PPGNTS neuron activation suppresses eating more potently than semaglutide alone. We conclude that central and peripheral GLP-1 systems suppress eating via independent gut–brain circuits, providing a rationale for pharmacological activation of PPGNTS neurons in combination with GLP-1 receptor agonists as an obesity treatment strategy.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
There are no publicly available datasets for this manuscript. All data necessary to interpret, replicate and build on the methods or findings reported here are contained within the manuscript and extended data figures. Primary data from ex vivo calcium recordings, food intake, metabolic and behavioural analyses, videos for BSS coding and photomicrographs for in situ hybridization and immunohistochemistry analyses are available in native format upon request from the corresponding authors. Access to stored tissue samples used for in situ hybridization and immunohistochemistry is available upon request from the corresponding authors. All mouse lines, plasmids and reagents used in this study have been previously published and/or are commercially available, and are detailed in the Reporting Summary. Further information and requests for resources and reagents should be directed to and will be fulfilled by S. Trapp (email@example.com).
Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. 10, 155 (2019).
Turton, M. D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996).
Trapp, S. & Richards, J. E. The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr. Opin. Pharmacol. 13, 964–969 (2013).
Müller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72–130 (2019).
Gaykema, R. P. et al. Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight. J. Clin. Invest. 127, 1031–1045 (2017).
Liu, J. et al. Enhanced AMPA Receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus. Neuron 96, 897–909.e5 (2017).
Holt, M. K. et al. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes 68, 21–33 (2019).
Zheng, H., Stornetta, R. L., Agassandian, K. & Rinaman, L. Glutamatergic phenotype of glucagon-like peptide 1 neurons in the caudal nucleus of the solitary tract in rats. Brain Struct. Funct. 220, 3011–3022 (2015).
Trapp, S. et al. PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309, R795–R804 (2015).
Cheng, W. et al. Leptin receptor–expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice. JCI Insight 5, e134359 (2020).
Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261–280 (1999).
Cork, S. C. et al. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol. Metab. 4, 718–731 (2015).
Card, J. P. et al. GLP-1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract. J. Comp. Neurol. 526, 2149–2164 (2018).
Hisadome, K., Reimann, F., Gribble, F. M. & Trapp, S. Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like peptide 1 neurons. Diabetes 59, 1890–1898 (2010).
Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
Krieger, J. P. Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms. Peptides 131, 170342 (2020).
Grill, H. J. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology 161, bqaa093 (2020).
Holt, M. K. et al. PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice. Mol. Metab. 39, 101024 (2020).
Secher, A. et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473–4488 (2014).
Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5, e133429 (2020).
Varin, E. M. et al. Distinct neural sites of GLP-1R expression mediate physiological versus pharmacological control of incretin action. Cell Rep. 27, 3371–3384.e3 (2019).
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J. & Hayes, M. R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152, 3103–3112 (2011).
Punjabi, M. et al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 155, 1690–1699 (2014).
Ast, J. et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat. Commun. 11, 1–18 (2020).
Krieger, J. P. et al. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes 65, 34–43 (2016).
Kim, K. S., Seeley, R. J. & Sandoval, D. A. Signalling from the periphery to the brain that regulates energy homeostasis. Nat. Rev. Neurosci. 19, 185–196 (2018).
Williams, E. K. K. et al. Sensory neurons that detect stretch and nutrients in the digestive system. Cell 166, 209–221 (2016).
Bai, L. et al. Genetic identification of vagal sensory neurons that control feeding. Cell 179, 1129–1143.e23 (2019).
Holt, M. K. et al. Synaptic inputs to the mouse dorsal vagal complex and its resident preproglucagon neurons. J. Neurosci. 39, 9767–9781 (2019).
Kreisler, A. D., Davis, E. A. & Rinaman, L. Differential activation of chemically identified neurons in the caudal nucleus of the solitary tract in non-entrained rats after intake of satiating vs. non-satiating meals. Physiol. Behav. 136, 47–54 (2014).
Nguyen, K. P., O’Neal, T. J., Bolonduro, O. A., White, E. & Kravitz, A. V. Feeding experimentation device (FED): a flexible open-source device for measuring feeding behavior. J. Neurosci. Methods 267, 108–114 (2016).
Kreisler, A. D. & Rinaman, L. Hindbrain glucagon-like peptide-1 neurons track intake volume and contribute to injection stress-induced hypophagia in meal-entrained rats. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 310, R906–R916 (2016).
Terrill, S. J. et al. Endogenous GLP-1 in lateral septum promotes satiety and suppresses motivation for food in mice. Physiol. Behav. 206, 191–199 (2019).
Ishii, Y. et al. Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol. Behav. 81, 129–140 (2004).
Wright, F. L. & Rodgers, R. J. Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. Psychopharmacology 231, 3729–3744 (2014).
Vrang, N., Phifer, C. B., Corkern, M. M. & Berthoud, H.-R. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am. J. Physiol. Integr. Comp. Physiol. 285, R470–R478 (2003).
Schwartz, G. J. & Moran, T. H. Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Neurosci. Biobehav. Rev. 20, 47–56 (1996).
Al Helaili, A., Park, S. J. & Beyak, M. J. Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents. Biochem. Biophys. Res. Commun. 533, 110–117 (2020).
Kanoski, S. E., Hayes, M. R. & Skibicka, K. P. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 310, R885–R895 (2016).
Yamaguchi, E., Yasoshima, Y. & Shimura, T. Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice. Physiol. Behav. 171, 158–164 (2017).
Hayes, M. R. & Schmidt, H. D. GLP-influences food and drug reward. Curr. Opin. Behav. Sci. 9, 66–70 (2016).
Anesten, F. et al. Preproglucagon neurons in the hindbrain have IL-6 receptor-α and show Ca2+ influx in response to IL-6. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 311, R115–R123 (2016).
Holt, M. K., Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M. & Trapp, S. Serotonergic modulation of the activity of GLP-1 producing neurons in the nucleus of the solitary tract in mouse. Mol. Metab. 6, 909–921 (2017).
Iwasaki, Y. et al. Peripheral oxytocin activates vagal afferent neurons to suppress feeding in normal and leptin-resistant mice: a route for ameliorating hyperphagia and obesity. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 308, R360–R369 (2015).
Iwasaki, Y. et al. Relay of peripheral oxytocin to central oxytocin neurons via vagal afferents for regulating feeding. Biochem. Biophys. Res. Commun. 519, 553–558 (2019).
Kawatani, M., Yamada, Y. & Kawatani, M. Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons. Peptides 107, 68–74 (2018).
Yamamoto, H. et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 23, 2939–2946 (2003).
Hisadome, K., Reimann, F., Gribble, F. M. & Trapp, S. CCK stimulation of GLP-1 neurons involves α 1-adrenoceptor- mediated increase in glutamatergic synaptic inputs. Diabetes 60, 2701–2709 (2011).
Adams, J. M. et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons. Diabetes 67, 1538–1548 (2018).
Fortin, S. M. et al. GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats. Sci. Transl. Med. 12, eaay8071 (2020).
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M. & Trapp, S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180, 111–121 (2011).
Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532–539 (2008).
Parker, H. E. et al. Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55, 2445–2455 (2012).
Richards, P. et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63, 1224–1233 (2014).
Han, W. et al. A neural circuit for gut-induced reward. Cell 175, 665–678 (2018).
Rakipovski, G. et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE−/− and LDLr−/− mice by a mechanism that includes inflammatory pathways. JACC Basic Transl. Sci. 3, 844–857 (2018).
de Lartigue, G., Ronveaux, C. C. & Raybould, H. E. Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity. Mol. Metab. 3, 595–607 (2014).
Friard, O. & Gamba, M. BORIS: a free, versatile open-source event-logging software for video/audio coding and live observations. Methods Ecol. Evol. 7, 1325–1330 (2016).
Halford, J. C., Wanninayake, S. C. & Blundell, J. E. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol. Biochem. Behav. 61, 159–168 (1998).
Rodgers, R. J., Holch, P. & Tallett, A. J. Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol. Biochem. Behav. 97, 3–14 (2010).
Mina, A. I. et al. CalR: a web-based analysis tool for indirect calorimetry experiments. Cell Metab. 28, 656–666.e1 (2018).
de Kloet, A. D. et al. Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. Brain Struct. Funct. 221, 891–912 (2016).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Wu, Z., Autry, A. E., Bergan, J. F., Watabe-Uchida, M. & Dulac, C. G. Galanin neurons in the medial preoptic area govern parental behaviour. Nature 509, 325–330 (2014).
Krashes, M. J. et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J. Clin. Invest. 121, 1424–1428 (2011).
Watabe-Uchida, M., Zhu, L., Ogawa, S. K., Vamanrao, A. & Uchida, N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74, 858–873 (2012).
Wickersham, I. R. et al. Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53, 639–647 (2007).
We thank L.B. Knudsen at Novo Nordisk for valuable discussions and provision of liraglutide and semaglutide. We also thank M. Arnold at ETH Zurich and Y. Tan at the University of Florida for their expert technical assistance, and K. Beier at UC Irvine for providing RABV for retrograde tracing. This study was supported by Medical Research Council (MRC) project grant no. MR/N02589X/1 to S.T. The initial collaboration between the Trapp, de Lartigue and Langhans laboratories, which generated this work was made possible thanks to a UCL Global Engagement Fund award to D.I.B., and a UCL Neuroscience ZNZ Collaboration award to S.T. and W.L. Research in the de Lartigue laboratory was funded by the NIH (NIDDK grant no. R01 DK116004) and with institutional support from the University of Florida College of Pharmacy. Research in the Reimann/Gribble laboratories was funded by the Wellcome Trust (grant nos. 106262/Z/14/Z and 106263/Z/14/Z) and the MRC (grant no. MRC_MC_UU_12012/3). Research in the Rinaman laboratory was funded by the US National Institutes of Health (grant nos. MH059911 and DK100685).
The F.R. and F.M.G. laboratory receives funding from AstraZeneca, Eli Lilly and LGM for unrelated research and F.M.G. consults for Kallyope (New York). All other authors have no competing interests to declare.
Peer review information Nature Metabolism thanks David D’Alessio, Kamal Rahmouni and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: George Caputa.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a, Experimental model and paradigm for metabolic phenotyping of PPGNTS-DTA mice (DTA, n = 8) or mCherry-transduced controls (mCh, n = 7). n = 8 (DTA) / 7 (mCh) animals for analyses presented in b-o. b, Cumulative hourly food intake over 1 day, 2-way mixed-model ANOVA: Virus F(1,13)=0.015, p = 0.904. c, Daily food intake by sex, 2-way mixed-model ANOVA: Virus F(1,11)=0.012, p = 0.914; Sex F(1,11)=0.683, p = 0.426. d, Directed ambulatory locomotion (excluding fine movements) over 1 day, 2-way mixed-model ANOVA: Virus F(1,11)=0.493, p = 0.497. e-i, Meal pattern and metabolic parameters over 1 day, unpaired 2-tailed t-test or Mann-Whitney U test: (e) U = 25, p = 0.779; (f) t(13)=0.997, p = 0.337; (g) t(13)=0.565, p = 0.582; (h) t(13)=0.797, p = 0.440; (i) t(13)=0.323, p = 0.752. j, Mean bodyweight over the 24 h test period, unpaired 2-tailed t-test: t(13)=0.883, p = 0.393. k,l, Food intake during dark and light phases, unpaired 2-tailed t-test: (k) t(13)=0.668, p = 0.516; (l) t(13)=1.251, p = 0.233. m, 24 h water intake, unpaired 2-tailed t-test: t(13)=0.205, p = 0.841. n, Ensure liquid diet preload intake, unpaired 2-tailed t-test: t(8)=0.219, p = 0.832; and post-Ensure chow intake, Mann-Whitney U test: U = 2, p = 0.038. o, Post-fast refeed intake, unpaired 2-tailed t-test: t(12)=2.501, p = 0.028. p-q, Hourly and cumulative intakes over 1 day from ad libitum eating PPGNTS-hM4Di mice (n = 8 animals), 2-way within-subjects ANOVA: (p) Drug F(1,7)=0.241, p = 0.639; (q) Drug F(1,7)=0.411, p = 0.542. r, Raster plot of chow pellet retrievals during the dark phase. Plots from the same mouse after saline and CNO injections presented adjacently. All data presented as mean ± SEM.
a, Non-cumulative hourly food intake over the circadian cycle from ad libitum eating PPGNTS-hM3Dq mice (n = 7 animals for analyses presented in a-b), 2-way within-subjects ANOVA: Drug x Time F(23,138)=4.599, p < 0.0001. b, Dark phase food intake by sex, 2-way mixed-model ANOVA: Drug F(1,5)=19.97, p = 0.0066; Sex F(1,5)=3.854, p = 0.107. c,d, Photomicrographs of colocalized cFos immunoreactivity and DIO-hM3Dq-mCherry in NTS of PPG-Cre:tdRFP mice perfused 3 hours after injection of saline or CNO (photomicrographs representative of independent experiments from 4/3 animals), cc: central canal. Scale=100 µm (inset 50 µm). e, Proportion of mCherry-expressing neurons co-localised with cFos-ir in mice perfused after administration of saline or CNO (n = 4 (SAL) / 3 (CNO) animals), unpaired 1-tailed t-test: t(5)=13.94, p < 0.0001. f, Non-cumulative hourly food intake over 1 day from 18 h fasted PPGNTS-hM3Dq mice (n = 7 animals for analyses presented in f-h), 2-way within-subjects ANOVA: Drug x Time F(23,138)=3.745, p < 0.0001. The behavioural satiety sequence (BSS) was analysed during the first 40 minutes of the dark phase. g,h, Food intake and eating rate over 40 minute BSS test, paired 2-tailed t-test and Wilcoxon matched pairs test: (g) t(6)=4.088, p = 0.0064; (h) W = 18, p = 0.156. All data presented as mean ± SEM.
a–c, Light phase food intake and metabolic parameters from ad libitum eating GLP-1RNodose-hM3Dq mice (n = 7 animals for analyses presented in a-c), paired 2-tailed t-test: (a) t(6)=0.0141, p = 0.989; (b) t(6)=0.952, p = 0.378; (c) t(6)=0.0406, p = 0.969. d, Photomicrographs of cFos immunoreactivity (cFos-ir) in coronal NTS sections from GLP-1R-Cre x PPG-YFP mice bilaterally injected in nodose ganglia with dye (Control) or AAV9-DIO-hM3Dq-mCherry (hM3Dq) and administered saline or CNO (photomicrographs representative of independent experiments from 3/3 animals). Distance in mm posterior to Bregma in bottom left, cc: central canal. Scale=100μm. e, cFos immunoreactive cells in the NTS (mean per section) of control) and hM3Dq mice (n = 3 animals per group for analyses in e-f), unpaired 2-tailed t-test: t(4)=2.981, p = 0.0407. f, PPGNTS neurons colocalised with cFos immunoreactivity in the NTS. Mann-Whitney 2-tailed U-test: U = 0, p = 0.100. g, Photomicrograph of nodose ganglion section from GLP-1R-Cre:tdRFP mouse injected with AAV encoding Cre-dependent channelrhodopsin and eYFP fluorescent reporter (DIO-CHR2-eYFP), and colocalisation of the tdRFP and eYFP reporters (photomicrographs representative of independent experiments from 4 animals). Scale=100 µm. h,i, Quantification of viral transduction specificity (h; co-localised cells as % (±SEM) of all eYFP+ cells) and efficiency (i; colocalised cells as % (±SEM) of all tdRFP+ cells), from a total of 374 tdRFP+ cells and 366 eYFP+ cells from the nodose ganglia of 3 mice. All data presented as mean ± SEM.
a, Photomicrograph of coronal NTS section from PPG-Cre:tdRFP mouse transduced with DIO-TVA-mCherry + DIO-RabiesG, and subsequently with rabies virus-ΔG-GFP (RABV). Bilateral NTS injection of TVA + RabiesG and counterbalanced unilateral injection of RABV (4 mice / side) resulted in 40.5% (±5.5) of all PPGNTS neurons being successfully transduced ‘starter’ neurons, identified by colocalisation of mCherry (and/or tdRFP) and GFP (photomicrographs in a-h representative of independent experiments from 8 animals). Despite unilateral RABV injection, starter neurons were observed in left and right NTS in all mice, indicating substantial viral spread and bilateral transduction. Scale=100μm. b, Total RABV + cells in left and right nodose ganglia (LNG / RNG; n = 6 / 7 biologically independent samples), unpaired 2-tailed t-test: t(11)=0.214, p = 0.834. c,d, Quantification of Glp1r and Oxtr colocalisation in nodose ganglia (c), and proportions of dual-expressing Glp1r / Oxtr cells colocalised with RABV (d). This dual population comprises 24.7% of all Glp1r cells and 19.7% of all Oxtr cells. 9% of RABV + vagal inputs to PPGNTS neurons express both Glp1r and Oxtr, and 26.1% of dual-expressing Glp1r / Oxtr cells are RABV + vagal inputs to PPGNTS neurons. e, Quantification of RABV and Glp1r colocalisation in NG as proportions of all RABV + cells and all Glp1r+ cells, including those Glp1r cells that also express Oxtr. f, Quantification of RABV and Oxtr colocalisation in NG as proportions of all RABV + cells and all Oxtr+ cells, including those Oxtr cells that also express Glp1r. g,h, Photomicrographs of left and right nodose ganglion sections showing rabies virus GFP expression (RABV) and Glp1r and Oxtr FISH. RABV + Glp1r colocalisation shown by white arrows, RABV + Oxtr by green arrows and RABV + Glp1r+Oxtr by white-edged green arrow. Scale=100μm. All data presented as mean ± SEM.
a,b, Food intake and bodyweight change over 1 day in eGFP and DTA mice (n = 5 (DTA) / 7 (eGFP) animals) administered oxytocin (0.4 mg/kg, i.p.), 2-way mixed-model ANOVA: (a) Drug F(1,10)=0.00474, p = 0.947; (b) Drug F(1,10)=0.0989, p = 0.760. c-d, Photomicrographs of coronal NTS sections from PPG-Cre:GCaMP3 mice injected with eGFP control virus (c) or DTA virus (d). Note the complete absence of green (GCaMP3-expressing, amplified by immunostaining against the GFP antigen) PPGNTS neurons in DTA-ablated tissue, and the extent of viral spread as demonstrated by constitutive expression of mCherry (photomicrographs representative of independent experiments from 7/5 animals). Distance in mm posterior to Bregma in bottom left, cc: central canal. Scale=100μm. All data presented as mean ± SEM.
a, Photomicrographs of coronal NTS section showing RABV expression, Glp1r FISH and TH-ir. RABV + Glp1r+TH-ir colocalisation shown by white-edged green arrows (photomicrographs representative of independent experiments from 4 animals). Scale=100μm (inset 20μm). b,c, Quantification of Glp1r and TH-ir co-localization in area postrema (b), and proportions of dual Glp1r / TH-ir cells co-localised with RABV (c). This dual population comprises 49.4% of all TH-ir cells and 31.2% of all Glp1r cells. 9.7% of RABV + AP inputs to PPGNTS neurons express Glp1r and are TH-ir, and 2.7% of dual Glp1r / TH-ir cells are RABV + AP inputs to PPGNTS neurons. All data presented as mean ± SEM.
a-e, Cumulative food intake by virus at 1,2,4,6 and 21 hr in eGFP and DTA mice (n = 8 (DTA) / 7 (eGFP) animals for analyses presented in (a-j) administered liraglutide (200 μg/kg, s.c.), 2-way mixed-model ANOVA: (a) Drug F(1,13)=0.246, p = 0.628; (b) Drug F(1,13)=2.108, p = 0.170; (c) Drug F(1,13)=37.44, p < 0.0001, Virus F(1,13)=0.836, p = 0.377; (d) Drug F(1,13)=75.09, p < 0.0001, Virus F(1,13)=1.877, p = 0.194; (e) Drug F(1,13)=154.9, p < 0.0001, Virus F(1,13)=1.272, p = 0.280. f-j, Cumulative food intake by virus at 1,2,4,6 and 21 hr in eGFP and DTA mice administered semaglutide (60 μg/kg, s.c.), 2-way mixed-model ANOVA: (f) Drug F(1,13)=1.965, p = 0.184; (g) Drug F(1,13)=17.1, p = 0.0012; Virus F(1,13)=0.630, p = 0.442; (h) Drug F(1,13)=82.49, p < 0.0001, Virus F(1,13)=0.332, p = 0.574; (i) Drug F(1,13)=98.21, p < 0.0001, Virus F(1,13)=0.840, p = 0.376; (j) Drug F(1,13)=126.1, p < 0.0001, Virus F(1,13)=3.42, p = 0.0873. k-m, Representative photomicrographs of cFos immunoreactivity (cFos-ir) in arcuate nucleus of the hypothalamus (ARC) 4 hours after vehicle (VEH, n = 4 animals) or semaglutide (SEMA, 60 μg/kg, s.c., n = 4 animals) administration, and total cFos count, unpaired 1-tailed t-test: m) t(6)=2.614, p = 0.020. Scale=100μm. (n-p) Representative photomicrographs of cFos-ir in paraventricular nucleus of the hypothalamus (PVN) 4 hours after vehicle or semaglutide administration (n = 4 / 4 animals), and total cFos count, unpaired 1-tailed t-test: (p) t(6)=5.109, p = 0.0011. Scale=100μm. q-t, Representative photomicrographs of cFos-ir in dorsal lateral and external lateral subdivisions of the parabrachial nucleus (dlPBN / elPBN) 4 hours after vehicle or semaglutide administration (n = 3 / 4 animals), and total cFos count, unpaired 1-tailed t-tests: (s) t(5)=1.693, p = 0.0756; (t) t(5)=3.57, p = 0.0080. Semaglutide did not increase cFos-ir in the medial PBN, t(5)=0.435, p = 0.341. Scale=100μm. All data presented as mean ± SEM.
a-d, Bodyweight change at 24 and 48 hours, and cumulative food intake at 48 and 72 hours (n = 6 animals), 1-way within-subjects ANOVA: (a) Drug F(2.1,10.5)=61.61, p < 0.0001; (b) Drug F(2.3,11.3)=102.7, p < 0.0001; (c) Drug F(2.1,10.6)=24.38, p < 0.0001; (d) Drug F(1.9,9.3)=40.35, p < 0.0001. 72 hr BW data not shown: Drug F(2.0,10.2)=4.22, p = 0.0454, no significant pairwise comparisons. e, Photomicrographs of coronal NTS sections from PPG-Cre:GCaMP3 mice injected with AAV encoding Cre-dependent hM3Dq and mCherry fluorescent reporter (DIO-hM3Dq-mCherry), and colocalisation of the GCaMP3 (amplified by immunostaining against GFP antigen) and mCherry reporters (photomicrographs representative of independent experiments from 4 animals). Distance in mm from Bregma in bottom left, cc: central canal. Scale=100 µm. f,g, Quantification of viral transduction specificity (f; co-localised cells as % (±SEM) of all mCherry+ cells) and efficiency (g; co-localised cells as % (±SEM) of all GCaMP3+ cells), from a total of 410 mCherry+ cells and 391 GCaMP3+ cells from 4 mice. All data presented as mean ± SEM.
About this article
Cite this article
Brierley, D.I., Holt, M.K., Singh, A. et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 3, 258–273 (2021). https://doi.org/10.1038/s42255-021-00344-4
Nature Communications (2021)
Nature Metabolism (2021)